Get the Stockscreener App
1.17
4.10%
-0.05
After Hours:
1.19
0.02
+1.71%
Inmune Bio Inc stock is traded at $1.17, with a volume of 2.46M.
It is down -4.10% in the last 24 hours and down -10.69% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.22
Open:
$1.27
24h Volume:
2.46M
Relative Volume:
5.74
Market Cap:
$31.10M
Revenue:
$50,000
Net Income/Loss:
$-49.89M
P/E Ratio:
-0.5468
EPS:
-2.1398
Net Cash Flow:
$-31.55M
1W Performance:
-10.69%
1M Performance:
-10.69%
6M Performance:
-38.42%
1Y Performance:
-85.63%
1-Day Range:
$1.16
$1.2913
1-Week Range:
$1.16
$1.39
52-Week Range:
$1.16
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.17 | 32.43M | 50,000 | -49.89M | -31.55M | -2.1398 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INMB PE Ratio & Valuation, Is INMB Overvalued - Intellectia AI
INMB Showcases Advancements in Alzheimer's Treatment at AD/PD 20 - GuruFocus
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - The Manila Times
Alzheimer’s trial gets plenary spotlight as blood markers guide treatment - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Rally Mode: Whats the profit margin of INmune Bio IncTrade Exit Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Outlook: Is INmune Bio Inc stock undervalued right nowPortfolio Risk Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Setup Watch: How liquid is INmune Bio Inc stockTrade Entry Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Gainers Report: How does INmune Bio Inc compare to its peersWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Will INmune Bio Inc benefit from geopolitical trends2026 Momentum & Free Community Supported Trade Ideas - baoquankhu1.vn
INmune Bio Inc Stock (ISIN: US45764T1060) Faces Analyst Hold Consensus Amid $8 Price Target - AD HOC NEWS
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of “Reduce” by Analysts - Defense World
INMB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Watch: Whats the RSI of INmune Bio Inc stockBreakout Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Breakout Zone: Is INmune Bio Inc stock undervalued right nowMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: What is the earnings history of INmune Bio IncJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Aug Intraday: Is CRBG undervalued by DCF analysisWeekly Earnings Recap & Weekly Momentum Picks - baoquankhu1.vn
Inmune Bio (INMB): Why This Beaten-Down Small-Cap Is Back on Risk Radars - AD HOC NEWS
INMB Technical Analysis & ETF Price Forecast - Intellectia AI
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next - TipRanks
INmune Bio Highlights CORDStrom RDEB Program and IP Strength - TipRanks
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio, Inc. advances therapies for rare disease impact beyond skin - Traders Union
INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data - National Today
INMB.O Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Decliners: What is the earnings history of INmune Bio IncJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):